DICLOFENAC SODIUM AND MISOPROSTOL (diclofenac sodium; misoprostol) by Novartis is delayed-release tablets is a combination product containing diclofenac sodium, an nsaid with analgesic, anti-inflammatory and antipyretic properties, and misoprostol, a gi mucosal protective prostaglandin-1 (pge1) analog. Approved for the signs, symptoms of osteoarthritis, rheumatoid arthritis in adult patients at high risk of developing nsaid-induced gastric and 4 more indications. First approved in 2023.
Drug data last refreshed 20h ago
delayed-release tablets is a combination product containing diclofenac sodium, an NSAID with analgesic, anti-inflammatory and antipyretic properties, and misoprostol, a GI mucosal protective prostaglandin-1 (PGE1) analog. Diclofenac The mechanism of action of diclofenac, like that of other NSAIDs,…
Worked on DICLOFENAC SODIUM AND MISOPROSTOL at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.